Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
Clinical trial NCT06751238 · RECRUITING
Trial details
- NCT number
- NCT06751238
- Sponsor
- Novartis Pharmaceuticals
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-24
- Primary completion
- 2032-11-30
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.